Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Tidal Investments LLC

Tidal Investments LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 6,350 shares of the biopharmaceutical company’s stock after acquiring an additional 510 shares during the quarter. Tidal Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $6,675,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blankinship & Foster LLC purchased a new position in Regeneron Pharmaceuticals in the third quarter worth approximately $2,081,000. Wilmington Savings Fund Society FSB lifted its stake in shares of Regeneron Pharmaceuticals by 193.4% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 1,810 shares of the biopharmaceutical company’s stock valued at $1,903,000 after purchasing an additional 1,193 shares during the last quarter. World Investment Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $44,221,000. Pine Valley Investments Ltd Liability Co increased its position in shares of Regeneron Pharmaceuticals by 19.0% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 5,303 shares of the biopharmaceutical company’s stock worth $5,575,000 after purchasing an additional 848 shares during the last quarter. Finally, Sculati Wealth Management LLC raised its holdings in Regeneron Pharmaceuticals by 1.9% in the 3rd quarter. Sculati Wealth Management LLC now owns 2,047 shares of the biopharmaceutical company’s stock valued at $1,970,000 after buying an additional 38 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the subject of several research analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. cut their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,099.90.

Regeneron Pharmaceuticals Stock Down 1.3 %

REGN stock opened at $731.30 on Friday. The stock has a market cap of $80.36 billion, a P/E ratio of 18.10, a PEG ratio of 2.32 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $728.68 and a twelve month high of $1,211.20. The company’s 50 day moving average is $849.77 and its two-hundred day moving average is $1,003.80.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.